We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly Tweaks Anticipated Phase III Alzheimer’s Drug Trial
Lilly Tweaks Anticipated Phase III Alzheimer’s Drug Trial
July 17, 2013
Eli Lilly plans to start a new Phase III trial in September to test its Alzheimer’s drug, solanezumab, but this time it will use a new brain scan technology to narrow the patient pool and only evaluate the drug for mild forms of the disease.